EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis

Thijs W de Vos iD, Ilonka Tersteeg, Enrico Lopriore, Dick Oepkes, Leendert Porcelijn, C Ellen van der Schoot, E Joanne T Verweij, Dian Winkelhorst, Masja de Haas iD, M Elske van den Akker-van Marle

Vox Sanguinis · 2025

DOI: 10.1111/vox.13779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2025. Verfasst von Thijs W de Vos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Antigens, Human Platelet, Prenatal Diagnosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Sanquin Bloedvoorziening, Process and Product Development Diagnostic Services at Sanquin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Foetal and neonatal alloimmune thrombocytopenia (FNAIT) results from maternal platelet‐directed antibodies and can result in severe intracranial haemorrhage (ICH) in foetuses and newborns. Screening for human platelet antigen‐1a (HPA‐1a)‐directed antibodies during pregnancy could allow timely intervention with antenatal treatment and prevent ICH. We assessed the cost effectiveness of HPA‐1a typing and anti‐HPA‐1a‐screening as part of the prenatal screening programme. Materials and Methods Different HPA‐1a screening scenarios were tested in a decision analysis model and assessed for diagnostic, treatment, intervention and lifetime costs and prevention effects compared to the current situation without screening in the Netherlands. Model parameters were based on available data, literature and expert opinions. One‐way sensitivity analysis and probabilistic sensitivity analysis were performed.

Results

Adding screening for anti‐HPA‐1a antibodies to the current antenatal screening programme of the Netherlands will lead to an additional cost of €4.7 million per year and a gain of 226 quality‐adjusted life years (QALYs) per year, indicating an incremental cost–effectiveness ratio (ICER) of €20,782 per QALY gained. One‐way sensitivity analysis showed that the uncertainty around the incidence of ICH, lifetime costs of disabled children and the probability of having antibody quantitation >3.0 IU/mL at 20 weeks had the highest effect on the ICER.

Conclusion

Antenatal anti‐HPA‐1a screening might be cost effective. To obtain more knowledge and thereby to improve risk stratification, a pilot screening programme is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocytopenia, Neonatal AlloimmuneAntigens, Human PlateletPrenatal DiagnosisHumansFemalePregnancyCost-Benefit AnalysisInfant, NewbornNetherlandsQuality-Adjusted Life YearsIsoantibodiesIntegrin beta3

Stichwörter der Autor:innen

HPA‐1a screeningcost–effectiveness analysisfoetal and neonatal alloimmune thrombocytopenia

Substanzen

Antigens, Human PlateletITGB3 protein, humanIsoantibodiesIntegrin beta3

Autor:innen und Institutionen

  • Willem-Alexander Children's Hospital, Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Experimental Immunohematology, Sanquin Research, Amsterdam, the Netherlands.
  • Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Amsterdam, the Netherlands.
  • Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Thijs W de Vos, Masja de Haas

Förderung

  • Stichting Sanquin Bloedvoorziening
  • Process and Product Development Diagnostic Services at Sanquin

Zitieren

APA

de Vos, T. W., Tersteeg, I., Lopriore, E., Oepkes, D., Porcelijn, L., van der Schoot, C. E., Verweij, E. J. T., Winkelhorst, D., de Haas, M., & van den Akker-van Marle, M. E. (2025). Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis. Vox Sanguinis. https://doi.org/10.1111/vox.13779

Vancouver

de Vos TW, Tersteeg I, Lopriore E, Oepkes D, Porcelijn L, van der Schoot CE, et al. Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis. Vox Sanguinis. 2025. doi:10.1111/vox.13779

BibTeX
@article{deVos2025,
  author = {de Vos, Thijs W and Tersteeg, Ilonka and Lopriore, Enrico and Oepkes, Dick and Porcelijn, Leendert and van der Schoot, C Ellen and Verweij, E Joanne T and Winkelhorst, Dian and de Haas, Masja and van den Akker-van Marle, M Elske},
  title = {Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis},
  journal = {Vox Sanguinis},
  year = {2025},
  doi = {10.1111/vox.13779}
}
Kostenlos starten →